Araris Biotech AG, a Swiss company pioneering proprietary antibody-drug conjugate (ADC)-linker technology, received a CHF 2.5M non-dilutive grant funding.
Innosuisse, the Swiss innovation agency committed to promote science-based innovation in the interest of the economy and society in Switzerland, has supported Araris through the Swiss Accelerator program for the development and advancement of its ADC candidates.
The non-dilutive funding will be used to develop and advance the company’s pipeline of ADC candidates, developed using its proprietary linker technology, towards the clinic.
Led by Philipp Spycher, Ph.D., chief executive officer and co-founder, Araris Biotech is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering.
Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.
FinSMEs
05/05/2023